Inhibition of PCSK9 leads to increased expression and decreased degradation of major histocompatibility complex class I (MHC I) proteins on tumor cells, leading to increased T cell infiltration of the tumor and improved anti-tumor activity [57,58,59]. The gene discussed is PCSK9; the disease is neoplasm.